Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.
Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, Lombardi L, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Omede' P, Tassone P, Boccadoro M, Palumbo A, Neri A, Musto P. Todoerti K, et al. Among authors: tassone p. Clin Cancer Res. 2013 Jun 15;19(12):3247-58. doi: 10.1158/1078-0432.CCR-12-3461. Epub 2013 Apr 18. Clin Cancer Res. 2013. PMID: 23599371
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Neri A, Marmiroli S, Tassone P, Lombardi L, Nobili L, Verdelli D, Civallero M, Cosenza M, Bertacchini J, Federico M, De Pol A, Deliliers GL, Sacchi S. Neri A, et al. Among authors: tassone p. Leuk Lymphoma. 2008 Jul;49(7):1374-83. doi: 10.1080/10428190802078289. Leuk Lymphoma. 2008. PMID: 18452078
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.
Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, Tagliaferri P. Correale P, et al. Among authors: tassone p. Clin Cancer Res. 2012 Feb 1;18(3):850-7. doi: 10.1158/1078-0432.CCR-10-3186. Epub 2011 Dec 5. Clin Cancer Res. 2012. PMID: 22142823 Clinical Trial.
Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A, Ave E, Zaffino F, Di Maira G, Ruzzene M, Adami F, Zambello R, Pitari MR, Tassone P, Pinna LA, Gurrieri C, Semenzato G, Piazza F. Manni S, et al. Among authors: tassone p. Clin Cancer Res. 2012 Apr 1;18(7):1888-900. doi: 10.1158/1078-0432.CCR-11-1789. Epub 2012 Feb 20. Clin Cancer Res. 2012. PMID: 22351691
MicroRNAs in the pathobiology of multiple myeloma.
Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A. Lionetti M, et al. Among authors: tassone p. Curr Cancer Drug Targets. 2012 Sep;12(7):823-37. doi: 10.2174/156800912802429274. Curr Cancer Drug Targets. 2012. PMID: 22671930 Review.
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Blotta S, et al. Among authors: tassone p. Blood. 2012 Dec 13;120(25):5002-13. doi: 10.1182/blood-2011-07-368142. Epub 2012 Jul 20. Blood. 2012. PMID: 22821765 Free PMC article.
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: tassone p. Clin Cancer Res. 2012 Nov 15;18(22):6260-70. doi: 10.1158/1078-0432.CCR-12-1708. Epub 2012 Oct 3. Clin Cancer Res. 2012. PMID: 23035210 Free PMC article.
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.
Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, Tassone P. Amodio N, et al. Among authors: tassone p. Oncotarget. 2012 Oct;3(10):1246-58. doi: 10.18632/oncotarget.675. Oncotarget. 2012. PMID: 23100393 Free PMC article.
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Leone E, et al. Among authors: tassone p. Clin Cancer Res. 2013 Apr 15;19(8):2096-106. doi: 10.1158/1078-0432.CCR-12-3325. Epub 2013 Feb 27. Clin Cancer Res. 2013. PMID: 23446999 Free PMC article.
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: tassone p. Oncotarget. 2013 Feb;4(2):242-55. doi: 10.18632/oncotarget.820. Oncotarget. 2013. PMID: 23479461 Free PMC article.
376 results